scholarly journals Assessing direct costs of treating metastatic triple-negative breast cancer in the USA

2020 ◽  
Author(s):  
Karen E Skinner ◽  
Amin Haiderali ◽  
Min Huang ◽  
Lee S Schwartzberg
Keyword(s):  
Breast Cancer ◽  
Emergency Department ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Emergency Department Visits ◽  
Monthly Cost ◽  
Effective Interventions ◽  
The Usa ◽  
The Mean ◽  
Record Review

Aim: Evaluation of monthly cost during metastatic triple-negative breast cancer (mTNBC) treatment. Patients & methods: Retrospective electronic medical record review of US females aged ≥18 years diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Mean monthly costs per patient were evaluated from start of mTNBC treatment until transfer to hospice, end of record or 3 months prior to death. Results: The mean monthly cost of first line was $21,908 for 505 treated patients; 50.2% of cost was attributable to hospitalization and emergency department visits, and 32.7% to anticancer therapy. Similar patterns were observed for subsequent lines of therapy. Conclusion: The majority of costs were attributable to hospitalization and emergency department services, suggesting a need for effective interventions to reduce utilization of costly services.

Exploring New Targets and Publication Tendency of Triple Negative Breast Cancer: A 20-Year Bibliometric Analysis

2021 ◽  
Author(s):  
Xiaonan Sheng ◽  
Huijuan Dai ◽  
Yonggang Song ◽  
Xueyun Ma
Keyword(s):  
Breast Cancer ◽  
Bibliometric Analysis ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Tumor Biology ◽  
Treatment Strategies ◽  
Gene Mutations ◽  
Research Focus ◽  
The Past ◽  
The Usa

Abstract Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and it lacks an efficient target treatment. Here, we aimed to gain knowledge on the development of TNBC research and explore potential treatment strategies.Methods: We analyzed 14,389 publications on TNBC from the Web of Science (WOS) over the past 20 years, from 2000 to 2020, using bibliometric methods. We evaluated the publication tendency of TNBC and the contributions of different countries. Institutions and journals with the highest number of TNBC publications were screened. Finally, the research focus of the TNBC publications were also analyzed.Results: TNBC publications have significantly increased in the past 20 years, with elevated relative research interest (RRI). The USA has the most TNBC-related publications with high quality, and China is the country with the most rapid growth tendency in TNBC publications. The University of Texas System is the institution with the most TNBC publications. Breast Cancer Research and Treatment is the journal that published the most TNBC-related publications. The top 30 publications with high citations are also listed. The researches focusing on TNBC in the past 20 years were separated into four main clusters: tumor biology, TNBC therapies, treatment sensitivity, and gene mutations. The research focus in TNBC ranked by appearing years reflects the development of TNBC treatment strategy, showing that targeting tumor immunity is now the main focus in TNBC research. Conclusions: Using bibliometric analysis, we initially revealed the increasing interest in TNBC research and summarized the publication tendency of TNBC. We also reported focused topics screened from publications in the past 20 years, indicating the main problems and research objectives of TNBC for the first time. Immune-related topics are becoming the focus of TNBC research.

scholarly journals A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status

2018 ◽  
Vol 12 ◽  
pp. 117955491879467 ◽  
Author(s):  
Ying-Wen Su ◽  
Chia-Yen Hung ◽  
Hung-Bun Lam ◽  
Yuan-Ching Chang ◽  
Po-Sheng Yang
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Brca Mutation ◽  
Clinical Stage ◽  
Univariate Analysis ◽  
Mutation Status ◽  
Clinicopathologic Factors ◽  
The Mean

The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and overall survival (OS) of patients with resected stage I-III TNBC who were treated with or without cisplatin-containing chemotherapy (CisCT or noCisCT) during 2004 and 2010. Of 129 patients, 25 received CisCT. In univariate analysis, the mean TTP for CisCT and noCisCT was 4.42 and 5.88 years, respectively ( P = .004). The mean OS for CisCT and noCisCT was 6.76 and 9.63 years, respectively ( P = .24). After adjusting for other clinicopathologic factors, only clinical stage II/III disease was independently associated with worse OS. The adjusted hazard ratio for CisCT was 1.48 ( P = .46) and was not statistically significant. In this small retrospective study, adding cisplatin to adjuvant chemotherapy for early TNBC with unknown BRCA mutation status did not benefit OS.

Effect of incorporation of cisplatin to adjuvant chemotherapy for triple-negative breast cancer patients of unknown BRCA mutation status on survival.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12009-e12009
Author(s):  
Chia-Yen Hung ◽  
Ying-Wen Su ◽  
Ruey Kuen Hsieh ◽  
Hung-Bun Lam ◽  
Yuan-Ching Chang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Brca Mutation ◽  
Stage I ◽  
Stage Ii ◽  
Rank Test ◽  
Mutation Status ◽  
Log Rank Test ◽  
The Mean

e12009 Background: Recently, adding platinum to neoadjuvant chemotherapy (C/T) was associated with improved response rate in early Triple-negative breast cancer (TNBC). Whether incorporation of platinum to adjuvant C/T was associated clinical benefit has not been well investigated. Methods: Patients with resected TNBC who had available staging information and complete treatment at Mackay Memorial Hospital between 2004 and 2010 were enrolled for retrieving cllinical and pathologic information. Patients were monitored until death or Jan 2015. Statistical analysis was performed to determine the association of cancer-related overall survival (OS) and clinicopathological features. For stage I/II patients, 18 out of 115 received cisplatin-containing C/T. The mean OS for stage I/II patients with and without cisplatin-containing C/T was 6.05 years (standard error [SE]: 0.72 ) and 9.55 years (SE: 0.31), respectively ( P=0.07; log-rank test). For stage II/III patients, 20 out of 81 received cisplatin-containing C/T. The mean OS for stage II/III patients with and without cisplatin-containing C/T was 6.51 years (SE: 0.64) and 8.65 years (SE: 0.38), respectively ( P=0.56; log-rank test). In multivariate analysis for stage I-III patients, only age was significantly associated with OS (adjusted hazard ratio [HR]: 1.05; 95% confidence interval [CI]: 1.00-1.10). The adjusted HR for adding cisplatin to adjuvant C/T was 2.17 (95% CI: 0.729-6.44). Conclusions: In this small-numbered retrospective study, adding cisplatin to adjuvant C/T for TNBC with unknown BRCA mutation status did not have OS benefit. [Table: see text]

scholarly journals Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey

2021 ◽  
pp. 297-304
Author(s):  
Saliha Karagöz Eren ◽  
Alaettin Arslan ◽  
Ebru Akay ◽  
Nail Özhan ◽  
Yunus Dönder
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
The Mean ◽  
Disease Free

Background: Triple-negative breast cancer (TNBC) is defined as tumors without estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This cancer is associated with higher rates of recurrence risk when compared to other subtypes of breast cancers. In this study, we aimed to explore the basic clinicopathological characteristics, prognosis, and recurrence patterns of TNBC patients. Methods: In the current study, forty-five TNBC female patients operated on for breast cancer in the General Surgery Clinic of Kayseri City Training and Research Hospital between 2016 and 2021 were included and retrospectively evaluated. Results: The percentage of TNBC was 12% of the 502 breast cancer patients who could access all three pieces of receptor information. The mean age of the patients was 58.9±15.2 years (27-90), and the mean BMI was 30.4±5.17 (21.5-40.6). It was observed that the most common histological subtype was invasive ductal carcinoma, and at the time of diagnosis, 11 patients were stage 1 (24.4%), 31 patients were stage 2 (68.8%), 2 patients were stage 3 (4.4%), and 1 patient was stage 4 (2.2%). During the follow-up period, 11 patients (24,4%) developed metastasis and the most common sites were the brain and bones. The mean time from diagnosis to metastasis was 20.7±5.75 (12-29) months.  The 3-year disease-free survival was 62%, and the 3-year overall survival (OS) was 70%.  Conclusion: TNBCs are cancers with varying prevalence, poor prognosis, and limited treatment alternatives. The prevalence of TNBC in our center was found to be lower than the literature rates and consistent with the literature, the lymph node stage was related to poor OS and disease free survival (DFS).

Identification of new therapeutic leads for triple negative breast cancer subtypes

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Therapeutic Leads

Immediate and long-term results of the first line chemotherapy in patients with metastatic triple negative breast cancer. Final analysis of randomized study

2020 ◽  
pp. 75-80
Author(s):  
S.A. Lyalkin ◽  
◽  
L.A. Syvak ◽  
N.O. Verevkina ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Randomized Study ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
Group 2 ◽  
Line Chemotherapy ◽  
Group 1

The objective: was to evaluate the efficacy of the first line chemotherapy in patients with metastatic triple negative breast cancer (TNBC). Materials and methods. Open randomized study was performed including 122 patients with metastatic TNBC. The efficacy and safety of the first line chemotherapy of regimens АТ (n=59) – group 1, patients received doxorubicine 60 мг/м2 and paclitaxel 175 мг/м2 and ТР (n=63) – group 2, patients received paclitaxel 175 мг/м2 and carboplatin AUC 5 were evaluated. Results. The median duration of response was 9.5 months (4.5–13.25 months) in patients received AT regimen and 8.5 months (4.7–12.25 months), in TP regimen; no statistically significant differences were observed, р=0.836. The median progression free survival was 7 months (95% CI 5–26 months) in group 1 and 7.5 months (95% CI 6–35 months) in group 2, p=0.85. Both chemotherapy regimens (AT and TP) had mild or moderate toxicity profiles (grade 1 or 2 in most patients). No significant difference in gastrointestinal toxicity was observed. The incidence of grade 3–4 neutropenia was higher in patients of group 2 (TP regimen): 42.8% versus 27% (р<0.05). Conclusions. Both regimens of chemotherapy (AT and TP) are appropriate to use in the first line setting in patients with metastatic TNBC. Key words: metastatic triple negative breast cancer, chemotherapy, progression free survival, chemotherapy toxicity.

Sign in / Sign up

Export Citation Format

Share Document